IMRX   $2.13  0.47% Market Open

Immuneering Corp
Last Events:

2023-08-09 Signal in Stochastic changed from bullish weakening to bearish. The stochastic indicator is in the lower part of the neutral territory and it falls. These factors indicate that negative dynamics persists. Last signal: down-crossing the middle level.

2023-08-09 Signal in MACD changed from bullish recovery to bullish weakening. Oscillator MACD is in the positive territory it's higher than the signal line and falls. These factors mean that the growing trend persists, but the growth rate is declining. Last signal: main and signal line crossing.

2023-08-09 Signal in RSI changed from bullish recovery to bearish. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.

2023-08-09 Signal in EMA20 changed from bullish reversal to bearish reversal. The price is trying to cross down the moving average line If the intersection will be successful, then a downside trend can be formed.

2023-08-06 Trend pattern changed from восходящий треугольник to симметричный треугольник.

2023-08-06 Signal in MACD changed from bullish weakening to bullish recovery. Oscillator MACD is in the positive territory it's higher than the signal line and grows. These factors mean that positive mood prevails. Last signal: main and signal line crossing.

2023-08-06 Signal in RSI changed from bullish weakening to bullish recovery. RSI indicator is in the upper part of the neutral territory and it heading north. These factors indicate that positive dynamics is recovering. Last signal: entrance to the overbought zone.

2023-08-05 Trend pattern changed from расходящийся клин с наклоном вверх to восходящий треугольник.


Current temperature: 3.96
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 7
Target Price Mean 11.21
Mean unverified/preliminary 11.21 / 11.21
Target Price Low / High 1.50 / 25.00
Median / STD DEV 12.00 / 7.80
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total None ActivelyBuy ActivelyBuy
rsi ActivelyBuy None ActivelyBuy
macd None None None
stoch None None None
ma20 None ActivelyBuy ActivelyBuy
ma50 None None None
ma100 None ActivelyBuy ActivelyBuy
Candlestick PatternNov. 4, 2024 Three Stars -
ISIN US45254E1073
ceo Dr. Benjamin J. Zeskind M.B.A., Ph.D.
Website https://immuneering.com
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.